Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas P Leist

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 13, 2019
Development and Validation of the FSIQ-RMS: A New Patient-Reported Questionnaire to Assess Symptoms and Impacts of Fatigue in Relapsing Multiple SclerosisStacie Hudgens, René Schüler, Jonathan Stokes, et al.
Drugs|November 28, 2020
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive ReviewKottil Rammohan, Patricia K Coyle, Elke Sylvester, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 21, 2018
Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD studyXavier Montalban, Thomas P Leist, Bruce A Cohen, et al.
Journal of Magnetic Resonance Imaging : JMRI|September 30, 2009
Toward a practical protocol for human optic nerve DTI with EPI geometric distortion correctionUdomchai Techavipoo, Annette F Okai, John Lackey, et al.
Frontiers in Neurology|March 3, 2020
N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory StudyDaniel A Monti, George Zabrecky, Thomas P Leist, et al.
Multiple Sclerosis and Related Disorders|December 7, 2016
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysisMark S Freedman, Xavier Montalban, Aaron E Miller, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 4, 2021
Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosisJiwon Oh, Bryan Walker, Gavin Giovannoni, et al.
Current Medical Research and Opinion|September 14, 2006
A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosisLloyd H Kasper, Daniel Everitt, Thomas P Leist, et al.
Neurodegenerative Disease Management|January 12, 2022
Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summaryJiwon Oh, Bryan Walker, Gavin Giovannoni, et al.
Frontiers in Immunology|January 10, 2022
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine TabletsGavin Giovannoni, Patricia K Coyle, Patrick Vermersch, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 13, 2019
Development and Validation of the FSIQ-RMS: A New Patient-Reported Questionnaire to Assess Symptoms and Impacts of Fatigue in Relapsing Multiple SclerosisStacie Hudgens, René Schüler, Jonathan Stokes, et al.
Drugs|November 28, 2020
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive ReviewKottil Rammohan, Patricia K Coyle, Elke Sylvester, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 21, 2018
Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD studyXavier Montalban, Thomas P Leist, Bruce A Cohen, et al.
Journal of Magnetic Resonance Imaging : JMRI|September 30, 2009
Toward a practical protocol for human optic nerve DTI with EPI geometric distortion correctionUdomchai Techavipoo, Annette F Okai, John Lackey, et al.
Frontiers in Neurology|March 3, 2020
N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory StudyDaniel A Monti, George Zabrecky, Thomas P Leist, et al.
Multiple Sclerosis and Related Disorders|December 7, 2016
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysisMark S Freedman, Xavier Montalban, Aaron E Miller, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 4, 2021
Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosisJiwon Oh, Bryan Walker, Gavin Giovannoni, et al.
Current Medical Research and Opinion|September 14, 2006
A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosisLloyd H Kasper, Daniel Everitt, Thomas P Leist, et al.
Neurodegenerative Disease Management|January 12, 2022
Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summaryJiwon Oh, Bryan Walker, Gavin Giovannoni, et al.
Frontiers in Immunology|January 10, 2022
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine TabletsGavin Giovannoni, Patricia K Coyle, Patrick Vermersch, et al.
Pageof 4